drugset
drugset / Trial / NCT04829305

A Trial of SHR2285 in Healthy Subjects

NCT04829305 ↗

Phase 1 Completed 31 enrolled Atridia Pty Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a phase 1 open-label study

Timeline

Start
2021-05-20
Primary completion
2021-09-06
Completion
2021-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR2285 Small molecule — Oral

Indications

No indication recorded.